Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: To evaluate the effectiveness and safety of direct acting antivirals (DAAs) available in chronic kidney disease (CKD) patients with hepatitis C virus (HCV) infection in Korea. Methods: In a retrospective, multicenter cohort study, 362 patients were enrolled from 2015 to 2019. The effectiveness and safety of DAAs including glecaprevir/pibrentasvir, sofosubvir/ribavirin, ledipasvir/sofosbuvir, and daclatasvir/asunaprevir were analyzed for patients according to CKD stage. We evaluated sustained virologic response at week 12 after treatment (SVR12) as primary endpoint. The effectiveness and safety were also evaluated according to CKD stage. Results: Among 362 patients, 307 patients completed DAAs treatment and follow-up period after end of treatment. The subjects comprised 87 patients (62 with CKD stage 3 and 25 with CKD stage (4–5), of whom 22 were undergoing hemodialysis). HCV patients with CKD stage 1 and 2 (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2) showed SVR12 of 97.2% and 95.4% respectively. SVR12 of CKD stage 3 and 4–5 (eGFR < 60 mL/min/1.73 m2) patients was 91.9% and 91.6% respectively. Patients undergoing hemodialysis achieved SVR12 (90.9%). Treatment failure of DAAs in stage 1, 2, 3, and 4–5 was 2.8%, 2.7%, 1.6%, and 4%. DAAs showed good safety profile and did not affect deterioration of renal function. Conclusions: DAAs shows comparable SVR12 and safety in CKD patients (stage 3, 4, and 5) with HCV compared with patients with stage 1 and 2. The effectiveness and safety of DAAs may be related to the treatment duration. Therefore, it is important to select adequate regimens of DAAs and to increase treatment adherence.
Abstract
Background/Aims: To evaluate the effectiveness and safety of direct acting antivirals (DAAs) available in chronic kidney disease (CKD) patients with hepatitis C virus (HCV) infection in Korea. Methods: In a retrospective, multicenter cohort study, 362 patients were enrolled from 2015 to 2019. The effectiveness and safety of DAAs including glecaprevir/pibrentasvir, sofosubvir/ribavirin, ledipasvir/sofosbuvir, and daclatasvir/asunaprevir were analyzed for patients according to CKD stage. We evaluated sustained virologic response at week 12 after treatment (SVR12) as primary endpoint. The effectiveness and safety were also evaluated according to CKD stage. Results: Among 362 patients, 307 patients completed DAAs treatment and follow-up period after end of treatment. The subjects comprised 87 patients (62 with CKD stage 3 and 25 with CKD stage (4–5), of whom 22 were undergoing hemodialysis). HCV patients with CKD stage 1 and 2 (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2) showed SVR12 of 97.2% and 95.4% respectively. SVR12 of CKD stage 3 and 4–5 (eGFR < 60 mL/min/1.73 m2) patients was 91.9% and 91.6% respectively. Patients undergoing hemodialysis achieved SVR12 (90.9%). Treatment failure of DAAs in stage 1, 2, 3, and 4–5 was 2.8%, 2.7%, 1.6%, and 4%. DAAs showed good safety profile and did not affect deterioration of renal function. Conclusions: DAAs shows comparable SVR12 and safety in CKD patients (stage 3, 4, and 5) with HCV compared with patients with stage 1 and 2. The effectiveness and safety of DAAs may be related to the treatment duration. Therefore, it is important to select adequate regimens of DAAs and to increase treatment adherence.
참고문헌 (37)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Hadziyannis SJ, "Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C : a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
- Fried MW, "Side effects of therapy of hepatitis C and their management", Hepatology, 36(5 Suppl 1), pp.S237~S244 (2002)
- Kohli A, "Treatment of hepatitis C : a systematic review", JAMA, 312, pp.631~640 (2014)
- Wedemeyer H, "Strategies to manage hepatitis C virus (HCV) disease burden", J Viral Hepat, 21(Suppl 1), pp.60~89 (2014)
- Cotter TG, "Improved graft survival after liver transplantation for recipients with hepatitis C virus in the direct-acting antiviral era", Liver Transpl, 25, pp.598~609 (2019)
- Welzel TM, "Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort", Gut, 65, pp.1861~1870 (2016)
- Chen YC, "A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease", Kidney Int, 85, pp.1200~1207 (2014)
- Lee JJ, "Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis", PLoS One, 9, pp.e100790~ (2014)
- Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group, "KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease", Kidney Int Suppl(2011), 8, pp.91~165 (2018)
- Rogal SS, "Incidence and progression of chronic kidney disease after hepatitis C seroconversion : results from ERCHIVES", Dig Dis Sci, 61, pp.930~936 (2016)
- Fabrizi F, "Impact of hepatitis C on survival in dialysis patients : a link with cardiovascular mortality?", J Viral Hepat, 19, pp.601~607 (2012)
- Fabrizi F, "Hepatitis C virus infection increases the risk of developing chronic kidney disease : a systematic review and meta-analysis", Dig Dis Sci, 60, pp.3801~3813 (2015)
- Khedmat H, "Hepatitis C virus infection in dialysis patients", Saudi J Kidney Dis Transpl, 25, pp.1~8 (2014)
- Ashkani-Esfahani S, "Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East : a systematic review and meta-analysis", World J Gastroenterol, 23, pp.151~166 (2017)
- Jadoul M, "Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients", Kidney Int, 95, pp.939~947 (2019)
- McGlynn EA, "Assessing the safety of direct-acting antiviral agents for hepatitis C", JAMA Netw Open, 2, pp.e194765~ (2019)
- Mansour M, "Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation", Transpl Infect Dis, 20, pp.e12972~ (2018)
- Garrison KL, "The drugdrug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection", Drug Metab Dispos, 46, pp.1212~1225 (2018)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
- Forns X, "Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis(EXPEDITION-1) : a single-arm, open-label, multicentre phase 3 trial", Lancet Infect Dis, 17, pp.1062~1068 (2017)
- Kumada H, "Efficacy and safety of glecaprevir", pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection, 2018, pp.53, 566~575
- Lin CW, "Pharmacokinetics, safety, and tolerability of single and multiple doses of ABT-493 : a first-in-human study", J Pharm Sci, 106, pp.645~651 (2017)
- Lin CW, "Pharmacokinetics, safety, and tolerability following single and multiple doses of pibrentasvir in a first-in-human study", Clin Pharmacol Drug Dev, 7, pp.44~52 (2018)
- Gane E, "Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment", N Engl J Med, 377, pp.1448~1455 (2017)
- Desmond Y. H. Yap, "Use of glecaprevir", pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment, 2020, pp.26(4), 554~561[DOI]
- McPhee F, "High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms", Adv Ther, 32, pp.637~649 (2015)
- Jong Eun Yeon, "Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD", IDSA and 2016 EASL, 2018, pp.24(3), 278~293[DOI]
- Jadoul M, "Hepatitis C treatment in chronic kidney disease patients : the kidney disease improving global outcomes perspective", Blood Purif, 43, pp.206~209 (2017)
- AASLD, "IDSA HCV Guidance Panel", Hepatitis C guidance : AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, 2015, pp.62, 932~954
- Roth D, "Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5chronic kidney disease(the C-SURFER study) : a combination phase 3 study", Lancet, 386, pp.1537~1545 (2015)
- Iliescu EL, "Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease", BMC Nephrol, 21, pp.21~ (2020)
- Liu CH, "Glecaprevir", pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment, 2020, pp.27, 568~575
- Elmowafy AY, "The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney disease", Int Urol Nephrol, 53, pp.749~761 (2021)
- Shebley M, "Mechanisms and Predictions of drug-drug interactions of the hepatitis C Virus three direct-acting antiviral regimen : paritaprevir", ritonavir, ombitasvir, and dasabuvir, 2017, pp.45, 755~764
- Li PK, "2018 Kidney Disease : Improving Global Outcomes(KDIGO)hepatitis C in chronic kidney disease guideline implementation : Asia Summit Conference report", Kidney Int Rep, 5, pp.1129~1138 (2020)
- Driedger M, "Direct acting antiviral HCV treatment does not influence renal function", Medicine(Baltimore), 99, pp.e20436~ (2020)